On August 18, 2016, Gray, Nathanael S.; Hatcher, John; Choi, Hwan Geun published a patent.Name: 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine The title of the patent was LRRK2 inhibitors and methods of making and using the same. And the patent contained the following:
The invention relates to compounds of formula I, II, and III as LRRK2 inhibitors; their preparation and use in the treatment of neurodegenerative diseases, such as Parkinson’s disease. Compounds of formula I wherein Rx is NRARB, substituted piperidinylmethanone, substituted morpholinomethanone, etc.; RA and RB are independently (un)substituted C1-6 alkyl and COR7; R7 is (un)substituted C1-6 alkyl, (un)substituted C2-6 alkenyl, (un)substituted C2-6 alkynyl; X1, X2 and X3 are independently N, NH and derivatives, substituted C; Rn is H and (un)substituted C1-6 alkyl; each R1 is independently (un)substituted C1-6 alkyl, (un)substituted C1-6 alkoxy and halo; m = 0 – 3; R2 is H, alkoxy, halo, etc.; and pharmaceutically acceptable salts thereof, are claimed. Example compound IV was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their LRRK2 inhibitory activity (some data given). The experimental process involved the reaction of 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine(cas: 98138-75-1).Name: 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine
The Article related to pyrrolopyrimidine preparation lrrk2 inhibitor treatment neurodegenerative disease, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Name: 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine
Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics